A Randomized Phase 2 Trial of Nivolumab Versus Nivolumab-Ipilimumab Combination in EGFR-Mutant NSCLC.
Lai GGY, Yeo JC, Jain A, Zhou S, Pang M, Alvarez JJS, Sim NL, Tan AC, Suteja L, Lim TW, Guo YA, Shen M, Saw SPL, Rohatgi N, Yeong JPS, Takano A, Lim KH, Gogna A, Too CW, Da Zhuang K, Tan WL, Kanesvaran R, Ng QS, Ang MK, Rajasekaran T, Wang L, Toh CK, Lim WT, Tam WL, Tan SH, Skanderup AMJ, Tan EH, Tan DSW.
Lai GGY, et al. Among authors: da zhuang k.
JTO Clin Res Rep. 2022 Sep 21;3(12):100416. doi: 10.1016/j.jtocrr.2022.100416. eCollection 2022 Dec.
JTO Clin Res Rep. 2022.
PMID: 36426287
Free PMC article.